Table 5 Comparison of ESBL prevalence in this study with some studies in Iran and other regions of the world
Region | Year | Authors | Method | Sample size and origin | ESBL prevalence |
|---|---|---|---|---|---|
Present study | 2023 | Afshari et al | Combined disk diffusion test | 106 E. coli isolates from 168 UTI cases | 52.8% |
Iran (North) | 2022 | Sadeghi et al | Combined disk diffusion test | 263 non-repetitive E. coli isolates from UTI cases | 46% |
Iran (Jiroft) | 2018 | Mashaiekhi et al | Combined disk diffusion test | 181 E.coli isolates from UTI cases | 58% |
Iran (Northeast) | 2015 | Harifi Mood et al | Combined disk diffusion test | 200 E. coli isolates from different clinical specimens | 42.5% |
China (Southwest) | 2020 | Sun et al | Vitek Compact 2 system | 7713 non-repetitive UPEC isolates | 49.7% |
Europe | 2020 | Critchley et al | CLSI MIC screening | 766 E. coli from UTI cases | 17.9% |
Africa (East) | 2016 | Sonda et al | Meta-analysis | 4076 Enterobacteriaceae isolates | 14%—89% |
Nigeria | 2012 | Ejikeugwu et al | Double disk synergy test | 83 non-repetitive E. coli isolates from suspected UTIs | 27.7% |
America (North) | 2016 | Lob et al | CLSI MIC screening | 3498 E. coli isolates from UTI cases | 7.8%—18.3% |
USA | 2021 | Kaye et al | Retrospective study | 1,513,882 E. coli isolates from UTI cases | 9.2% |